-
1
-
-
20044380769
-
Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction
-
Hu G, Jousilahti P, Qiao Q, Katoh S, Tuomilehto J. Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. Diabetologia. 2005;48(5):856-61.
-
(2005)
Diabetologia
, vol.48
, Issue.5
, pp. 856-861
-
-
Hu, G.1
Jousilahti, P.2
Qiao, Q.3
Katoh, S.4
Tuomilehto, J.5
-
2
-
-
84930465070
-
Standards of medical care in diabetes-2015
-
American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Suppl 1):S1-93.
-
(2015)
Diabetes Care
, vol.38
, pp. S1-S93
-
-
-
3
-
-
84919999219
-
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
-
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-9.
-
(2015)
Diabetes Care
, vol.38
, Issue.1
, pp. 140-149
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
Diamant, M.4
Ferrannini, E.5
Nauck, M.6
-
4
-
-
53749096863
-
10-year follow-up of intensive glucose control in type 2 diabetes
-
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89.
-
(2008)
N Engl J Med
, vol.359
, Issue.15
, pp. 1577-1589
-
-
Holman, R.R.1
Paul, S.K.2
Bethel, M.A.3
Matthews, D.R.4
Neil, H.A.5
-
5
-
-
33947399316
-
Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care
-
Cook MN, Girman CJ, Stein PP, Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care. Diabet Med. 2007;24(4):350-8.
-
(2007)
Diabet Med
, vol.24
, Issue.4
, pp. 350-358
-
-
Cook, M.N.1
Girman, C.J.2
Stein, P.P.3
Alexander, C.M.4
-
6
-
-
79955752170
-
Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations
-
Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602-13.
-
(2011)
Ann Intern Med
, vol.154
, Issue.9
, pp. 602-613
-
-
Bennett, W.L.1
Maruthur, N.M.2
Singh, S.3
Segal, J.B.4
Wilson, L.M.5
Chatterjee, R.6
-
7
-
-
84862302997
-
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
-
Gallwitz B, Guzman J, Dotta F, Guerci B, Simó R, Basson BR, et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet. 2012;379(9833):2270-8.
-
(2012)
Lancet
, vol.379
, Issue.9833
, pp. 2270-2278
-
-
Gallwitz, B.1
Guzman, J.2
Dotta, F.3
Guerci, B.4
Simó, R.5
Basson, B.R.6
-
8
-
-
18144388647
-
Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia
-
American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28(5):1245-9.
-
(2005)
Diabetes Care
, vol.28
, Issue.5
, pp. 1245-1249
-
-
-
9
-
-
32144448938
-
Standards of medical care in diabetes-2006
-
American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care. 2006;29(Suppl 1):S4-42.
-
(2006)
Diabetes Care
, vol.29
, pp. S4-S42
-
-
-
10
-
-
84872944068
-
Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
-
MacConell L, Pencek R, Li Y, Maggs D, Porter L. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes. 2013;6:31-41.
-
(2013)
Diabetes Metab Syndr Obes.
, vol.6
, pp. 31-41
-
-
MacConell, L.1
Pencek, R.2
Li, Y.3
Maggs, D.4
Porter, L.5
-
11
-
-
84928428071
-
Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial
-
Wysham CH, MacConell LA, Maggs DG, Zhou M, Griffin PS, Trautmann ME. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial. Mayo Clin Proc. 2015;90(3):356-65.
-
(2015)
Mayo Clin Proc
, vol.90
, Issue.3
, pp. 356-365
-
-
Wysham, C.H.1
MacConell, L.A.2
Maggs, D.G.3
Zhou, M.4
Griffin, P.S.5
Trautmann, M.E.6
-
12
-
-
59449101432
-
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
-
Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473-81.
-
(2009)
Lancet
, vol.373
, Issue.9662
, pp. 473-481
-
-
Garber, A.1
Henry, R.2
Ratner, R.3
Garcia-Hernandez, P.A.4
Rodriguez-Pattzi, H.5
Olvera-Alvarez, I.6
-
13
-
-
79951906623
-
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2years as monotherapy compared with glimepiride in patients with type 2 diabetes
-
Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B, et al. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(4):348-56.
-
(2011)
Diabetes Obes Metab
, vol.13
, Issue.4
, pp. 348-356
-
-
Garber, A.1
Henry, R.R.2
Ratner, R.3
Hale, P.4
Chang, C.T.5
Bode, B.6
-
14
-
-
84923887216
-
Twelve-month treatment with liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients
-
Russo GT, Labate AM, Giandalia A, Romeo EL, Villari P, Alibrandi A, et al. Twelve-month treatment with liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients. J Endocrinol Invest. 2014;38(1):81-9.
-
(2014)
J Endocrinol Invest
, vol.38
, Issue.1
, pp. 81-89
-
-
Russo, G.T.1
Labate, A.M.2
Giandalia, A.3
Romeo, E.L.4
Villari, P.5
Alibrandi, A.6
-
15
-
-
33947156808
-
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
-
Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007;29(1):139-53.
-
(2007)
Clin Ther
, vol.29
, Issue.1
, pp. 139-153
-
-
Buse, J.B.1
Klonoff, D.C.2
Nielsen, L.L.3
Guan, X.4
Bowlus, C.L.5
Holcombe, J.H.6
-
16
-
-
38549162147
-
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
-
Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24(1):275-86.
-
(2008)
Curr Med Res Opin
, vol.24
, Issue.1
, pp. 275-286
-
-
Klonoff, D.C.1
Buse, J.B.2
Nielsen, L.L.3
Guan, X.4
Bowlus, C.L.5
Holcombe, J.H.6
-
17
-
-
84864757433
-
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
-
Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-83.
-
(2012)
Lancet
, vol.380
, Issue.9840
, pp. 475-483
-
-
Gallwitz, B.1
Rosenstock, J.2
Rauch, T.3
Bhattacharya, S.4
Patel, S.5
Eynatten, M.6
-
18
-
-
77955048324
-
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
-
Matthews DR, Dejager S, Ahren B, Fonseca V, Ferrannini E, Couturier A, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12(9):780-9.
-
(2010)
Diabetes Obes Metab
, vol.12
, Issue.9
, pp. 780-789
-
-
Matthews, D.R.1
Dejager, S.2
Ahren, B.3
Fonseca, V.4
Ferrannini, E.5
Couturier, A.6
-
19
-
-
77958184434
-
Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition
-
Bunck MC, Diamant M, Eliasson B, Corner A, Shaginian RM, Heine RJ, et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care. 2010;33(8):1734-7.
-
(2010)
Diabetes Care
, vol.33
, Issue.8
, pp. 1734-1737
-
-
Bunck, M.C.1
Diamant, M.2
Eliasson, B.3
Corner, A.4
Shaginian, R.M.5
Heine, R.J.6
-
20
-
-
84982732820
-
Add-on treatment with liraglutide improves glycemic control in patients with type 2 diabetes on metformin therapy
-
Chiefari E, Capula C, Vero A, Oliverio R, Puccio L, Liguori R, et al. Add-on treatment with liraglutide improves glycemic control in patients with type 2 diabetes on metformin therapy. Diabetes Technol Ther. 2015;17(7):468-74.
-
(2015)
Diabetes Technol Ther.
, vol.17
, Issue.7
, pp. 468-474
-
-
Chiefari, E.1
Capula, C.2
Vero, A.3
Oliverio, R.4
Puccio, L.5
Liguori, R.6
-
21
-
-
67349136326
-
Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes
-
Papathanassiou K, Naka KK, Kazakos N, Kanioglou C, Makriyiannis D, Pappas K, et al. Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes. Atherosclerosis. 2009;205(1):221-6.
-
(2009)
Atherosclerosis.
, vol.205
, Issue.1
, pp. 221-226
-
-
Papathanassiou, K.1
Naka, K.K.2
Kazakos, N.3
Kanioglou, C.4
Makriyiannis, D.5
Pappas, K.6
-
22
-
-
84893183343
-
Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients
-
Li CJ, Yu Q, Yu P, Yu TL, Zhang QM, Lu S, et al. Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients. Cardiovasc Diabetol. 2014;13:36.
-
(2014)
Cardiovasc Diabetol
, vol.13
, pp. 36
-
-
Li, C.J.1
Yu, Q.2
Yu, P.3
Yu, T.L.4
Zhang, Q.M.5
Lu, S.6
-
23
-
-
0034604248
-
Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS)
-
Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102(1):42-7.
-
(2000)
Circulation
, vol.102
, Issue.1
, pp. 42-47
-
-
Festa, A.1
D'Agostino, R.2
Howard, G.3
Mykkanen, L.4
Tracy, R.P.5
Haffner, S.M.6
-
24
-
-
0036230414
-
Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study
-
Festa A, D'Agostino R Jr, Tracy RP, Haffner SM, Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51(4):1131-7.
-
(2002)
Diabetes
, vol.51
, Issue.4
, pp. 1131-1137
-
-
Festa, A.1
D'Agostino, R.2
Tracy, R.P.3
Haffner, S.M.4
-
25
-
-
19944429519
-
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease
-
Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352(1):29-38.
-
(2005)
N Engl J Med
, vol.352
, Issue.1
, pp. 29-38
-
-
Nissen, S.E.1
Tuzcu, E.M.2
Schoenhagen, P.3
Crowe, T.4
Sasiela, W.J.5
Tsai, J.6
-
26
-
-
33646381127
-
High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study
-
Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care. 2006;29(2):329-33.
-
(2006)
Diabetes Care
, vol.29
, Issue.2
, pp. 329-333
-
-
Soinio, M.1
Marniemi, J.2
Laakso, M.3
Lehto, S.4
Ronnemaa, T.5
-
27
-
-
35148814453
-
Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin
-
Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract. 2007;13(5):444-50.
-
(2007)
Endocr Pract.
, vol.13
, Issue.5
, pp. 444-450
-
-
Viswanathan, P.1
Chaudhuri, A.2
Bhatia, R.3
Al-Atrash, F.4
Mohanty, P.5
Dandona, P.6
-
28
-
-
0032511580
-
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
-
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-13.
-
(1998)
BMJ
, vol.317
, Issue.7160
, pp. 703-713
-
-
-
29
-
-
0032513878
-
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group
-
Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755-62.
-
(1998)
Lancet
, vol.351
, Issue.9118
, pp. 1755-1762
-
-
Hansson, L.1
Zanchetti, A.2
Carruthers, S.G.3
Dahlof, B.4
Elmfeldt, D.5
Julius, S.6
-
30
-
-
84864797983
-
Investigation of the haemodynamic effects of exenatide in healthy male subjects
-
Mendis B, Simpson E, MacDonald I, Mansell P. Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol. 2012;74(3):437-44.
-
(2012)
Br J Clin Pharmacol
, vol.74
, Issue.3
, pp. 437-444
-
-
Mendis, B.1
Simpson, E.2
MacDonald, I.3
Mansell, P.4
-
31
-
-
84864360856
-
Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide
-
Paul S, Best J, Klein K, Han J, Maggs D. Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide. Diabetes Obes Metab. 2012;14(9):826-34.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.9
, pp. 826-834
-
-
Paul, S.1
Best, J.2
Klein, K.3
Han, J.4
Maggs, D.5
-
32
-
-
84866729956
-
Patterns of weight change associated with long-term weight change and cardiovascular disease risk factors in the Look AHEAD Study
-
Neiberg RH, Wing RR, Bray GA, Reboussin DM, Rickman AD, Johnson KC, et al. Patterns of weight change associated with long-term weight change and cardiovascular disease risk factors in the Look AHEAD Study. Obesity (Silver Spring). 2012;20(10):2048-56.
-
(2012)
Obesity (Silver Spring).
, vol.20
, Issue.10
, pp. 2048-2056
-
-
Neiberg, R.H.1
Wing, R.R.2
Bray, G.A.3
Reboussin, D.M.4
Rickman, A.D.5
Johnson, K.C.6
-
33
-
-
84882304221
-
Effect of lifestyle intervention on cardiometabolic risk factors: results of the POWER-UP trial
-
Vetter ML, Wadden TA, Chittams J, Diewald LK, Panigrahi E, Volger S, et al. Effect of lifestyle intervention on cardiometabolic risk factors: results of the POWER-UP trial. Int J Obes (Lond). 2013;37(Suppl 1):S19-24.
-
(2013)
Int J Obes (Lond)
, vol.37
, pp. S19-S24
-
-
Vetter, M.L.1
Wadden, T.A.2
Chittams, J.3
Diewald, L.K.4
Panigrahi, E.5
Volger, S.6
-
34
-
-
84924289309
-
Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
-
Blonde L, Pencek R, MacConell L. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:12.
-
(2015)
Cardiovasc Diabetol
, vol.14
, pp. 12
-
-
Blonde, L.1
Pencek, R.2
MacConell, L.3
-
35
-
-
84859867948
-
Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors
-
Varanasi A, Patel P, Makdissi A, Dhindsa S, Chaudhuri A, Dandona P. Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors. Endocr Pract. 2012;18(2):140-5.
-
(2012)
Endocr Pract
, vol.18
, Issue.2
, pp. 140-145
-
-
Varanasi, A.1
Patel, P.2
Makdissi, A.3
Dhindsa, S.4
Chaudhuri, A.5
Dandona, P.6
-
36
-
-
0347423198
-
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
-
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-52.
-
(2003)
Hypertension
, vol.42
, Issue.6
, pp. 1206-1252
-
-
Chobanian, A.V.1
Bakris, G.L.2
Black, H.R.3
Cushman, W.C.4
Green, L.A.5
Izzo, J.L.6
-
37
-
-
84880015206
-
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
-
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-357.
-
(2013)
J Hypertens
, vol.31
, Issue.7
, pp. 1281-1357
-
-
Mancia, G.1
Fagard, R.2
Narkiewicz, K.3
Redon, J.4
Zanchetti, A.5
Bohm, M.6
-
38
-
-
84875178118
-
Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals
-
Meloni AR, DeYoung MB, Han J, Best JH, Grimm M. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals. Cardiovasc Diabetol. 2013;12:48.
-
(2013)
Cardiovasc Diabetol
, vol.12
, pp. 48
-
-
Meloni, A.R.1
DeYoung, M.B.2
Han, J.3
Best, J.H.4
Grimm, M.5
-
39
-
-
84936977599
-
Characterization of heart rate increases with glucagon-like peptide-1 agonist therapy
-
Chilton R, MacConell LA, Han JC, Marso SP. Characterization of heart rate increases with glucagon-like peptide-1 agonist therapy. Circulation. 2013;128(Suppl 22):A16290.
-
(2013)
Circulation
, vol.128
, pp. A16290
-
-
Chilton, R.1
MacConell, L.A.2
Han, J.C.3
Marso, S.P.4
-
40
-
-
84877749349
-
Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter
-
Valensi P, Chiheb S, Fysekidis M. Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter. Diabetologia. 2013;56(6):1196-200.
-
(2013)
Diabetologia
, vol.56
, Issue.6
, pp. 1196-1200
-
-
Valensi, P.1
Chiheb, S.2
Fysekidis, M.3
-
41
-
-
84901593760
-
Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities
-
Lund A, Knop FK, Vilsboll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur J Intern Med. 2014;25(5):407-14.
-
(2014)
Eur J Intern Med
, vol.25
, Issue.5
, pp. 407-414
-
-
Lund, A.1
Knop, F.K.2
Vilsboll, T.3
-
42
-
-
84964695799
-
Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists
-
Saraiva FK, Sposito AC. Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc Diabetol. 2014;13(1):142.
-
(2014)
Cardiovasc Diabetol
, vol.13
, Issue.1
, pp. 142
-
-
Saraiva, F.K.1
Sposito, A.C.2
-
43
-
-
33748442464
-
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82weeks in 314 overweight patients with type 2 diabetes
-
Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8(4):436-47.
-
(2006)
Diabetes Obes Metab
, vol.8
, Issue.4
, pp. 436-447
-
-
Blonde, L.1
Klein, E.J.2
Han, J.3
Zhang, B.4
Mac, S.M.5
Poon, T.H.6
-
44
-
-
51749110866
-
Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride
-
Rubin CJ, Ledeine JM, Fiedorek FT. Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride. Diab Vasc Dis Res. 2008;5(3):168-76.
-
(2008)
Diab Vasc Dis Res.
, vol.5
, Issue.3
, pp. 168-176
-
-
Rubin, C.J.1
Ledeine, J.M.2
Fiedorek, F.T.3
-
45
-
-
79951702236
-
Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database
-
Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care. 2011;34(1):90-5.
-
(2011)
Diabetes Care
, vol.34
, Issue.1
, pp. 90-95
-
-
Best, J.H.1
Hoogwerf, B.J.2
Herman, W.H.3
Pelletier, E.M.4
Smith, D.B.5
Wenten, M.6
-
46
-
-
79959259385
-
Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials
-
Monami M, Cremasco F, Lamanna C, Colombi C, Desideri CM, Iacomelli I, et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res. 2011;2011:215764.
-
(2011)
Exp Diabetes Res
, vol.2011
, pp. 215764
-
-
Monami, M.1
Cremasco, F.2
Lamanna, C.3
Colombi, C.4
Desideri, C.M.5
Iacomelli, I.6
-
47
-
-
79952694840
-
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
-
Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol. 2011;10:22.
-
(2011)
Cardiovasc Diabetol
, vol.10
, pp. 22
-
-
Ratner, R.1
Han, J.2
Nicewarner, D.3
Yushmanova, I.4
Hoogwerf, B.J.5
Shen, L.6
-
48
-
-
84875385071
-
Treatment with exenatide once weekly or twice daily for 30weeks is associated with changes in several cardiovascular risk markers
-
Chiquette E, Toth PP, Ramirez G, Cobble M, Chilton R. Treatment with exenatide once weekly or twice daily for 30weeks is associated with changes in several cardiovascular risk markers. Vasc Health Risk Manag. 2012;8:621-9.
-
(2012)
Vasc Health Risk Manag.
, vol.8
, pp. 621-629
-
-
Chiquette, E.1
Toth, P.P.2
Ramirez, G.3
Cobble, M.4
Chilton, R.5
-
49
-
-
84865130603
-
Addition of liraglutide in patients with type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function
-
Forst T, Michelson G, Ratter F, Weber MM, Anders S, Mitry M, et al. Addition of liraglutide in patients with type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med. 2012;29(9):1115-8.
-
(2012)
Diabet Med
, vol.29
, Issue.9
, pp. 1115-1118
-
-
Forst, T.1
Michelson, G.2
Ratter, F.3
Weber, M.M.4
Anders, S.5
Mitry, M.6
-
50
-
-
84914165449
-
Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls
-
Bannister CA, Holden SE, Jenkins-Jones S, Morgan CL, Halcox JP, Schernthaner G, et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab. 2014;16(11):1165-73.
-
(2014)
Diabetes Obes Metab
, vol.16
, Issue.11
, pp. 1165-1173
-
-
Bannister, C.A.1
Holden, S.E.2
Jenkins-Jones, S.3
Morgan, C.L.4
Halcox, J.P.5
Schernthaner, G.6
-
51
-
-
84910150364
-
Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women
-
Li Y, Hu Y, Ley SH, Rajpathak S, Hu FB. Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women. Diabetes Care. 2014;37(11):3106-13.
-
(2014)
Diabetes Care
, vol.37
, Issue.11
, pp. 3106-3113
-
-
Li, Y.1
Hu, Y.2
Ley, S.H.3
Rajpathak, S.4
Hu, F.B.5
-
52
-
-
0014914649
-
A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results
-
Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19(Suppl):789-830.
-
(1970)
Diabetes
, vol.19
, Issue.SUPPL
, pp. 789-830
-
-
Meinert, C.L.1
Knatterud, G.L.2
Prout, T.E.3
Klimt, C.R.4
-
53
-
-
84860117993
-
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
-
Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731.
-
(2009)
BMJ
, vol.339
, pp. b4731
-
-
Tzoulaki, I.1
Molokhia, M.2
Curcin, V.3
Little, M.P.4
Millett, C.J.5
Ng, A.6
-
54
-
-
0032511566
-
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group
-
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854-65.
-
(1998)
Lancet
, vol.352
, Issue.9131
, pp. 854-865
-
-
|